Andreyev

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, HCPCS, Gait, Patient, Operating cost, Stroke, Sale, Acquisition, HSDT, Andreyev, Social services, ATM, Pons, Medicare, FDA, CMS, PTAP, Food, Video game

NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Gross profit for the fourth quarter of 2023 was $44 thousand, compared to gross profit of $132 thousand in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 decreased to a loss of $2.2 million, compared to an operating loss of $2.7 million in the fourth quarter of 2022.
  • Net loss was $1.0 million for the fourth quarter of 2023, compared to a net loss of $4.9 million in the fourth quarter of 2022.
  • The basic and diluted net loss per share for the fourth quarter 2023 was $1.47, compared to net loss per share of $8.66 in the fourth quarter 2022.

Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
School, Social services, Pons, Gait, TBI, Patient, HCPCS, UPC, Andreyev, PTAP, Research, HSDT, Wolters Kluwer, Accreditation, Stroke, Rehabilitation, Multiple sclerosis, Letter, Pacific Blue Cross, Pharmaceutical industry, Cryptocurrency, Security (finance), Health insurance, Video game, Helios, Health

NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023.

Key Points: 
  • NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023.
  • Together with the previously announced Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) accreditation, the UPC numbers allow for dual paths of reimbursement.
  • Research and development expenses for the third quarter of 2023 decreased slightly to $722 thousand, compared to $751 thousand in the third quarter of 2022.
  • Total operating expenses for the third quarter of 2023 decreased to $3.1 million, compared to $4.9 million in the third quarter of 2022.

Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Survivor, Montefiore Medical Center, CMS, Accreditation, Stroke, Gait, Centers for Medicare & Medicaid Services, Pons, HSDT, The Compliance Team, Medical school, Multiple sclerosis, MS, TCT, Food and Drug Administration, Medicare, Andreyev, ATM, Medical University of South Carolina, Patient, PTAP, MUSC, Growth, Research, FDA, Durable medical equipment, Pharmaceutical industry, Health insurance, Video game, Cryptocurrency, Helios

NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended June 30, 2023.

Key Points: 
  • “We saw a significant increase in sales during the second quarter of 2023, with revenue up 115% over the second quarter of 2022, and up 131% compared to the first quarter of 2023.
  • Selling, general and administrative expenses for the second quarter of 2023 were $2.6 million, comparable to the $2.5 million reported in the second quarter of 2022.
  • Total operating expenses for the second quarter of 2023 decreased to $3.3 million, compared to $3.5 million in the second quarter of 2022.
  • Operating loss for the second quarter of 2023 decreased $0.2 million to a loss of $3.2 million, compared to an operating loss of $3.4 million in the second quarter of 2022.

Helius Medical Technologies Announces DMEPOS Accreditation for PoNS

Retrieved on: 
Tuesday, June 20, 2023
Management of multiple sclerosis, Helios, CMS, Legislation, Accreditation, Centers for Medicare & Medicaid Services, Pons, HSDT, The Compliance Team, Stroke, Multiple sclerosis, TCT, Certification, Medicare, Emerging technologies, Andreyev, Health, Organization

The accreditation certifies that Helius has established processes that conform to TCT’s Exemplary Provider® DMEPOS Quality Standards.

Key Points: 
  • The accreditation certifies that Helius has established processes that conform to TCT’s Exemplary Provider® DMEPOS Quality Standards.
  • “We are thrilled that PoNS has been awarded DMEPOS accreditation.
  • “DMEPOS accreditation has particular relevance under the proposed Transitional Coverage for Emerging Technologies (TCET) legislation.
  • TCT’s proprietary accreditation status is known as Exemplary Provider Accreditation® and its industry-leading accreditation model features healthcare’s first comprehensive set of plain language, operations-driven quality standards with expert-led implementation guidance.

Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

Retrieved on: 
Monday, April 17, 2023
Real, Management of multiple sclerosis, Helios, PMID, Gait, DSM-IV codes, Pons, AAN, HSDT, Stroke, Therapy, Clinical trial, American Academy, Brain, Falls, Multiple sclerosis, MS, Nerve, The United People of Canada, Andreyev, FGA, Rehabilitation, Patient, Annual Meetings of the International Monetary Fund and the World Bank Group, Risk, Traumatic brain injury, DGI, Exhibition, Boston Convention and Exhibition Center, American Academy of Neurology, Health Canada, Tongue, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Dietary supplement, Pharmaceutical industry, Medical device

Helius’s presence at the conference comes at a time when PoNS is seeking additional indications for neurological conditions that lead to gait and/or balance impairment.

Key Points: 
  • Helius’s presence at the conference comes at a time when PoNS is seeking additional indications for neurological conditions that lead to gait and/or balance impairment.
  • Health Canada authorized PoNS for short-term treatment of balance and gait deficit due to MS, mild-to-moderate traumatic brain injury (mmTBI) and, in the past month, stroke .
  • “This is the right time to exhibit at the AAN conference,” said Helius President and Chief Executive Officer Dane Andreeff.
  • Tyler M, Skinner K, Prabhakaran V, Kaczmarek K, Danilov Y. Translingual neurostimulation for the treatment of chronic symptoms due to mild-to-moderate traumatic brain injury.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
MS, Pons, Clinical trial, HSDT, Introduction, Management of multiple sclerosis, Andreyev, PTAP, Patient, Therapy, Stroke, Health, Center of excellence, Operating cost, Prescription, Video game, Pharmaceutical industry, Cryptocurrency, Helios

NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2022.

Key Points: 
  • Gross profit for the fourth quarter of 2022 was $132 thousand, compared to gross profit of $129 thousand in the fourth quarter of 2021.
  • Operating expenses for the fourth quarter of 2022 decreased to $2.8 million, compared to $4.2 million in the fourth quarter of 2021.
  • Operating loss for the fourth quarter of 2022 decreased $1.4 million to a loss of $2.7 million, compared to an operating loss of $4.1 million in the fourth quarter of 2021.
  • The basic and diluted net loss per share for the fourth quarter 2022 was $0.17, compared to net loss per share of $1.31 in the fourth quarter 2021.